Wren
Download Wren on the App Store

Mounjaro, Zepbound and birth control pills: the 4-week rule

Updated · Wren editorial team · sources: FDA prescribing information and peer-reviewed studies

Yes — tirzepatide (Mounjaro, Zepbound) can make birth control pills less effective. Both labels advise switching to a non-oral method, or adding a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after every dose increase. Non-oral hormonal methods (the patch, ring, injection, implant or hormonal IUD) are not expected to be affected. The label for the GLP-1 pill Foundayo (orforglipron) gives the same advice for 30 days.

Why tirzepatide affects the pill

GLP-1 medicines slow how quickly the stomach empties. A pill you swallow has to pass through the stomach before it is absorbed, so slower emptying can lower how much of the hormone reaches your bloodstream. The Mounjaro and Zepbound labels note that this delay is largest after the first dose and diminishes over time, which is why the precaution is tied to starting and to each step up in dose rather than lasting forever.

What each label says

Oral contraceptive advice in GLP-1 prescribing information (checked November 2026)
MedicineActive ingredientWhat the label advisesFor how long
Mounjarotirzepatide (injection)Switch to a non-oral method or add a barrier method4 weeks after starting and after each dose increase
Zepboundtirzepatide (injection)Switch to a non-oral method or add a barrier method4 weeks after starting and after each dose increase
Foundayoorforglipron (tablet)Switch to a non-oral method or add a barrier method30 days after starting and after each dose increase

Non-oral hormonal methods — the patch, vaginal ring, injection, implant and hormonal IUD — “should not be affected,” according to the tirzepatide labels.

Which weeks count as a dose increase?

Tirzepatide is usually started at a low dose and stepped up every few weeks. Each step is a new 4-week window. For example, if you start on week 1 and increase your dose on week 5 and week 9, the windows run from week 1 to week 4, week 5 to week 8, and week 9 to week 12. If you stay on the same dose afterwards, no new window starts.

What to ask your prescriber

Know when your backup weeks start and end

Wren marks the 4 weeks after each tirzepatide start or dose increase on your calendar, next to your cycle and dose days.

Download Wren on the App Store

Frequently asked questions

Does Mounjaro or Zepbound make the pill not work?

It can make oral hormonal contraceptives less reliable. The labels explain that tirzepatide delays gastric emptying, which is largest after the first dose and diminishes over time, so they advise a non-oral method or a barrier method for 4 weeks after starting and after each dose increase.

How long do I need backup contraception on tirzepatide?

For 4 weeks after your first dose and for 4 weeks after each dose escalation, according to the Mounjaro and Zepbound prescribing information. Ask your prescriber how this applies to your plan.

Does this affect the patch, ring, IUD or implant?

The tirzepatide labels say hormonal contraceptives that are not taken by mouth should not be affected. Copper and hormonal IUDs are not taken by mouth.

What about Ozempic or Wegovy?

The 4-week advice appears in the tirzepatide labels (Mounjaro, Zepbound) and, as 30 days, in the Foundayo label. If you take a different GLP-1 with the pill, ask your prescriber or pharmacist whether any precautions apply to you.

How does Wren help with this?

If you tell Wren you take tirzepatide and a birth control pill, it flags the 4 weeks after you start or increase your dose and reminds you to ask your prescriber about a backup method. Wren does not give contraception advice itself.

Sources

  1. MOUNJARO (tirzepatide) prescribing information — Eli Lilly via DailyMed (NIH), label effective August 27, 2026
  2. ZEPBOUND (tirzepatide) prescribing information — Eli Lilly via DailyMed (NIH), label effective August 28, 2026
  3. FOUNDAYO (orforglipron) prescribing information — Eli Lilly via DailyMed (NIH), label effective July 29, 2026